Research programme: amyotrophic lateral sclerosis therapy - ALS Therapy Development Institute

Drug Profile

Research programme: amyotrophic lateral sclerosis therapy - ALS Therapy Development Institute

Alternative Names: ALS TDI 00846; TDI 104; TDI 142; TDI 158; TDI 163; TDI 168; TDI 186; TDI 197; TDI 201; TDI 202; TDI 206; TDI 207; TDI 208; TDI 209; TDI 210; TDI 211; TDI 28; TDI 53

Latest Information Update: 22 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ALS Therapy Development Institute
  • Class Gene therapies; Small molecules
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 30 Mar 2010 ALS TDI 00846 is available for partnering for clinical development (http://www.als.net)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top